Pregnancy outcomes in mixed connective tissue disease: a multicentre study.

OBJECTIVES In this study we aimed to investigate foetal and maternal pregnancy outcomes from a large multicentre cohort of women diagnosed with MCTD and anti-U1RNP antibodies. METHODS This multicentre retrospective cohort study describes the outcomes of 203 pregnancies in 94 consecutive women ever pregnant who fulfilled the established criteria for MCTD with confirmed U1RNP positivity. RESULTS The foetal outcomes in 203 pregnancies were as follows: 146 (71.9%) live births, 38 (18.7%) miscarriages (first trimester pregnancy loss of <12 weeks gestation), 18 (8.9%) stillbirths (pregnancy loss after 20 weeks gestation) and 11 (5.4%) cases with intrauterine growth restriction. Maternal pregnancy outcomes were as follows: 8 (3.9%) developed pre-eclampsia, 2 (0.9%) developed eclampsia, 31 (15.3%) developed gestational hypertension and 3 (1.5%) developed gestational diabetes. Women with MCTD and aPL and pulmonary or muscular involvement had worse foetal outcomes compared with those without. Moreover, we report a case of complete congenital heart block (0.45%) and a case of cutaneous neonatal lupus, both born to a mother with positive isolated anti-U1RNP and negative anti-Ro/SSA antibodies. CONCLUSION In our multicentre cohort, women with MCTD had a live birth rate of 72%. While the true frequency of heart block associated with anti-U1RNP remains to be determined, this study might raise the consideration of echocardiographic surveillance in this setting. Pregnancy counselling should be considered in women with MCTD.

[1]  M. Wahren-Herlenius,et al.  Benefits of fetal echocardiographic surveillance in pregnancies at risk of congenital heart block: single‐center study of 212 anti‐Ro52‐positive pregnancies , 2019, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[2]  J. Cnota,et al.  Prenatal heart block screening in mothers with SSA/SSB autoantibodies: Targeted screening protocol is a cost‐effective strategy , 2018, Congenital Heart Disease.

[3]  M. Donofrio,et al.  Home Monitoring for Fetal Heart Rhythm During Anti-Ro Pregnancies. , 2018, Journal of the American College of Cardiology.

[4]  N. Costedoat-Chalumeau,et al.  Should we treat congenital heart block with fluorinated corticosteroids? , 2017, Autoimmunity reviews.

[5]  M. Halushka,et al.  Clinical and pathologic implications of extending the spectrum of maternal autoantibodies reactive with ribonucleoproteins associated with cutaneous and now cardiac neonatal lupus from SSA/Ro and SSB/La to U1RNP. , 2017, Autoimmunity reviews.

[6]  M. Mosca,et al.  Pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Practical messages from the EULAR guidelines. , 2017, Polish archives of internal medicine.

[7]  R. Fischer-Betz,et al.  EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome , 2015, Annals of the rheumatic diseases.

[8]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.

[9]  P. Ravani,et al.  Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. , 2016, Journal of autoimmunity.

[10]  K. Sliwa,et al.  Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology , 2016, European journal of heart failure.

[11]  C. Gordon,et al.  Systemic lupus erythematosus , 2016, Nature Reviews Disease Primers.

[12]  Mimi Y. Kim,et al.  Predictors of Pregnancy Outcomes in Patients With Lupus , 2015, Annals of Internal Medicine.

[13]  J. Buyon,et al.  The clinical spectrum of autoimmune congenital heart block , 2015, Nature Reviews Rheumatology.

[14]  R. Watson,et al.  Neonatal Lupus Syndrome Associated with Ribonucleoprotein Antibodies , 2013, Pediatric dermatology.

[15]  J. Buyon,et al.  Umbilical cord blood levels of maternal antibodies reactive with p200 and full‐length Ro 52 in the assessment of risk for cardiac manifestations of neonatal lupus , 2012, Arthritis care & research.

[16]  Mimi Y. Kim,et al.  Maternal Use of Hydroxychloroquine Is Associated With a Reduced Risk of Recurrent Anti-SSA/Ro-Antibody–Associated Cardiac Manifestations of Neonatal Lupus , 2012, Circulation.

[17]  M. Halushka,et al.  Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus. , 2012, Rheumatology.

[18]  L. Tam,et al.  Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus , 2011, Lupus.

[19]  J. Gran,et al.  The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients , 2011, Annals of the rheumatic diseases.

[20]  Kent R Bailey,et al.  A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[21]  D. Friedman,et al.  Doppler fetal mechanical PR interval prolongation with positive maternal anti‐RNP but negative SSA/Ro and SSB/La auto‐antibodies , 2010, Prenatal diagnosis.

[22]  Y. Peñate,et al.  Histopathologic characteristics of neonatal cutaneous lupus erythematosus: description of five cases and literature review , 2009, Journal of cutaneous pathology.

[23]  J. Lam,et al.  Anti-RNP neonatal lupus in a female newborn , 2009, Lupus.

[24]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[25]  C. Laskin,et al.  Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period. , 2005, The Journal of rheumatology.

[26]  R. Kitridou.  Pregnancy in mixed connective tissue disease. , 2005, Rheumatic diseases clinics of North America.

[27]  M. Zeher,et al.  Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). , 2003, Clinical and experimental rheumatology.

[28]  Takuya Takahashi,et al.  Neonatal lupus erythematosus associated with maternal mixed connective tissue disease , 2003, Pediatrics International.

[29]  R. Cimaz,et al.  Ultraviolet light exposure is not a requirement for the development of cutaneous neonatal lupus , 2002, Lupus.

[30]  W. Weston,et al.  Neonatal lupus erythematosus. , 2002, Dermatology nursing.

[31]  A. Shalita,et al.  Neonatal lupus erythematosus: discordant disease expression of U1RNP-positive antibodies in fraternal twins--is this a subset of neonatal lupus erythematosus or a new distinct syndrome? , 1995, Journal of the American Academy of Dermatology.

[32]  E. Silverman,et al.  U1RNP positive neonatal lupus erythematosus: association with anti‐La antibodies? , 1995, The British journal of dermatology.

[33]  D. Alarcón-Segovia,et al.  Mixed connective tissue disease and overlap syndromes. , 1994, Clinics in dermatology.

[34]  M. Petri,et al.  Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort. , 1993, The Journal of rheumatology.

[35]  L. Lee.  Neonatal lupus erythematosus. , 1993, The Journal of investigative dermatology.

[36]  R. Watson,et al.  U1RNP antibody-positive neonatal lupus. A report of two cases with immunogenetic studies. , 1992, Archives of dermatology.

[37]  H. Ohto,et al.  Neonatal lupus erythematosus in Japan. , 1992, Journal of the American Academy of Dermatology.

[38]  I. Lundberg,et al.  Pregnancy outcome in patients with high titer anti-RNP antibodies. A retrospective study of 40 pregnancies. , 1991, The Journal of rheumatology.

[39]  S. T. Glass,et al.  Neonatal lupus erythematosus simulating transient myasthenia gravis at presentation. , 1991, The Journal of pediatrics.

[40]  D. Alarcón-Segovia,et al.  Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. , 1989, The Journal of rheumatology.

[41]  J. Harley,et al.  The neonatal lupus syndrome associated with U1RNP (nRNP) antibodies. , 1987, The New England journal of medicine.

[42]  H. Holman,et al.  Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. , 1976, The New England journal of medicine.

[43]  H. Holman,et al.  Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). , 1972, The American journal of medicine.